1. Home
  2. USNA vs PHAR Comparison

USNA vs PHAR Comparison

Compare USNA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • PHAR
  • Stock Information
  • Founded
  • USNA 1992
  • PHAR 1988
  • Country
  • USNA United States
  • PHAR Netherlands
  • Employees
  • USNA N/A
  • PHAR N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • USNA Health Care
  • PHAR Health Care
  • Exchange
  • USNA Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • USNA 565.2M
  • PHAR 718.1M
  • IPO Year
  • USNA 1996
  • PHAR N/A
  • Fundamental
  • Price
  • USNA $30.77
  • PHAR $11.00
  • Analyst Decision
  • USNA Hold
  • PHAR Strong Buy
  • Analyst Count
  • USNA 1
  • PHAR 3
  • Target Price
  • USNA $36.00
  • PHAR $30.00
  • AVG Volume (30 Days)
  • USNA 156.7K
  • PHAR 3.0K
  • Earning Date
  • USNA 07-22-2025
  • PHAR 07-31-2025
  • Dividend Yield
  • USNA N/A
  • PHAR N/A
  • EPS Growth
  • USNA N/A
  • PHAR N/A
  • EPS
  • USNA 1.82
  • PHAR N/A
  • Revenue
  • USNA $876,242,000.00
  • PHAR $320,708,000.00
  • Revenue This Year
  • USNA $13.04
  • PHAR $13.31
  • Revenue Next Year
  • USNA $7.36
  • PHAR $7.68
  • P/E Ratio
  • USNA $16.83
  • PHAR N/A
  • Revenue Growth
  • USNA N/A
  • PHAR 24.13
  • 52 Week Low
  • USNA $23.10
  • PHAR $6.65
  • 52 Week High
  • USNA $48.85
  • PHAR $12.61
  • Technical
  • Relative Strength Index (RSI)
  • USNA 57.59
  • PHAR 51.11
  • Support Level
  • USNA $29.68
  • PHAR $10.23
  • Resistance Level
  • USNA $31.20
  • PHAR $11.21
  • Average True Range (ATR)
  • USNA 0.70
  • PHAR 0.27
  • MACD
  • USNA 0.01
  • PHAR -0.14
  • Stochastic Oscillator
  • USNA 77.49
  • PHAR 34.01

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: